80
Participants
Start Date
July 25, 2018
Primary Completion Date
January 20, 2022
Study Completion Date
March 25, 2022
Fitusiran
Pharmaceutical form: solution for injection Route of administration: subcutaneous
BPA prophylaxis
Pharmaceutical form: solution for injection Route of administration: Intravenous
Factor (FVIII or FIX) prophylaxis
Pharmaceutical form: solution for injection Route of administration: Intravenous
Investigational Site Number 5301, Crumlin
Investigational Site Number 4501, Copenhagen
Investigational Site Number 6104, Prahran
Investigational Site Number 8204, Seoul
Investigational Site Number 3902, Milan
Investigational Site Number 9008, Gaziantep
Investigational Site Number 9005, Istanbul
Investigational Site Number 9010, Izmir
Investigational Site Number 8202, Daejeon
Investigational Site Number 9009, Kayseri
Investigational Site Number 9701, Ramat Gan
Investigational Site Number 9006, Samsun
Investigational site number 9013, Van
Investigational Site Number 6004, Ampang
Investigational Site Number 3303, Lyon
Investigational Site Number 8002, Lviv
Investigational Site Number 6002, Johor Bahru
Investigational Site Number 6003, Kota Kinabalu
Investigational Site Number 0139, Los Angeles
Investigational Site Number 8604, Beijing
Investigational Site Number 8101, Nagoya
Investigational Site Number 8102, Nishinomiya
Investigational Site Number 8104, Saitama
Investigational Site Number 8109, Tokyo
Investigational Site Number 5201, San Pablo
Investigational Site Number 8201, Busan
Investigational Site Number 9002, Adana
Investigational Site Number 9001, Ankara
Investigational Site Number 9004, Antalya
Investigational Site Number 9003, Izmir
Investigational Site Number 8003, Kyiv
Investigational Site Number 4402, Glasgow
Investigational Site Number 4407, London
Investigational Site Number 4403, London
Investigational Site Number 4401, London
Genzyme, a Sanofi Company
INDUSTRY